Literature DB >> 16965186

Medical risk in patients with bipolar disorder and schizophrenia.

John W Newcomer1.   

Abstract

Patients with schizophrenia and bipolar disorder are vulnerable to developing key modifiable risk factors for cardiovascular disease, such as obesity, smoking, hypertension, dyslipidemia, and type 2 diabetes mellitus. In addition, mood stabilizers, anticonvulsants, and antipsychotic medications, which are commonly used to treat schizophrenia and bipolar disorder, have been linked to risk for adverse metabolic changes in patients. This article reviews the current literature on the prevalence of medical risk factors in the general population as well as in those patients with schizophrenia or bipolar disorder and discusses treatment strategies and lifestyle changes that patients can make in order to reduce their risks for certain diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16965186

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  26 in total

1.  A motivational interviewing group to manage cardiometabolic risk on an inpatient psychiatry unit.

Authors:  Paul B Shagoury; Melinda Currier; Jeffrey C Fetter
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

2.  Presence of an interaction between smoking and being overweight increases risks of hypertension, diabetes, and cardiovascular disease in outpatients with mood disorders.

Authors:  Midori Nishiyama; Michio Kimijima; Takashi Muto; Kazumoto Kimura
Journal:  Environ Health Prev Med       Date:  2011-11-08       Impact factor: 3.674

3.  Mental illness and cardiovascular mortality: searching for the links.

Authors:  David S Goldbloom; Paul Kurdyak
Journal:  CMAJ       Date:  2007-03-13       Impact factor: 8.262

4.  An epidemiologic and clinical overview of medical and psychopathological comorbidities in major psychoses.

Authors:  A Carlo Altamura; Marta Serati; Alessandra Albano; Riccardo A Paoli; Ira D Glick; Bernardo Dell'Osso
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-02-18       Impact factor: 5.270

Review 5.  Management of adverse effects of mood stabilizers.

Authors:  Andrea Murru; Dina Popovic; Isabella Pacchiarotti; Diego Hidalgo; Jordi León-Caballero; Eduard Vieta
Journal:  Curr Psychiatry Rep       Date:  2015-08       Impact factor: 5.285

6.  Treating bipolar disorder in the primary care setting: the role of aripiprazole.

Authors:  J Sloan Manning; Susan L McElroy
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2009

7.  Resource utilization and cost in a commercially insured population with schizophrenia.

Authors:  Kathryn Fitch; Kosuke Iwasaki; Kathleen F Villa
Journal:  Am Health Drug Benefits       Date:  2014-01

8.  Investigation of serum high-sensitive C-reactive protein levels across all mood states in bipolar disorder.

Authors:  Angelo B Cunha; Ana C Andreazza; Fabiano A Gomes; Benicio N Frey; Leonardo E da Silveira; Carlos A Gonçalves; Flávio Kapczinski
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-02-23       Impact factor: 5.270

Review 9.  Interventions to Address Medical Conditions and Health-Risk Behaviors Among Persons With Serious Mental Illness: A Comprehensive Review.

Authors:  Emma E McGinty; Julia Baller; Susan T Azrin; Denise Juliano-Bult; Gail L Daumit
Journal:  Schizophr Bull       Date:  2015-07-28       Impact factor: 9.306

Review 10.  Bipolar and major depressive disorder: neuroimaging the developmental-degenerative divide.

Authors:  Jonathan Savitz; Wayne C Drevets
Journal:  Neurosci Biobehav Rev       Date:  2009-01-21       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.